chlorozinc(1+),2-methanidyl-2-methylpropane | 116212-82-9

• 分子结构分类: 有机化合物 - 有机盐 - 有机金属盐
• 英文名称: chlorozinc(1+),2-methanidyl-2-methylpropane
• 英文别名: ZnCl(neopentyl)；neopentyl zinc chloride；neopentylzinc chloride；neopentylzinc iodide
• CAS: 116212-82-9
• 化学式: C₅H₁₁ClZn
• 分子量: 171.985
• InChiKey: UXSQEBPYPCNIFN-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  2.69
• 重原子数：
  7.0
• 可旋转键数：
  1.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0.0
• 氢给体数：
  0.0
• 氢受体数：
  0.0

反应信息

• 作为反应物：
  描述：

  (S)-7-bromo-1,2,3,4-tetrahydro--1-naphthylaminee 、 chlorozinc(1+),2-methanidyl-2-methylpropane 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 作用下， 反应 12.0h， 以86%的产率得到7-(2,2-dimethyl-propyl)-1,2,3,4-tetrahydro-naphthalen-1-ylamine
  参考文献：
  名称：

  [EN] 2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES
  [FR] 1,3-DIAMINOPROPANES A SUBSTITUTION 2-AMINO- ET 2-THIO-

  摘要：

  公开号：

  WO2005095326A3
• 作为产物：
  描述：

  1-溴-2,2-二甲基丙烷 在 magnesium 、 zinc(II) chloride 作用下， 以 四氢呋喃 为溶剂， 生成 chlorozinc(1+),2-methanidyl-2-methylpropane
  参考文献：
  名称：

  [EN] 2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES
  [FR] 1,3-DIAMINOPROPANES A SUBSTITUTION 2-AMINO- ET 2-THIO-

  摘要：

  公开号：

  WO2005095326A3

文献信息

• [EN] METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS<br/>[FR] PROCEDES DE TRAITEMENT D'AMYLOIDOSE UTILISANT DES INHIBITEURS DE PROTEASE ASPARTYLE
  申请人：ELAN PHARM INC

  公开号：WO2005070407A1

  公开（公告）日：2005-08-04

  The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

  这项发明涉及乙酰2-羟基-1,3-二氨基螺环己烷及其衍生物，可用于治疗与淀粉样变性相关的疾病、疾病和症状。淀粉样变性是指与A-beta蛋白异常沉积相关的一系列疾病、疾病和症状。
• Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
  申请人：John Varghese

  公开号：US20060014737A1

  公开（公告）日：2006-01-19

  The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

  这项发明涉及新型化合物和治疗与淀粉样变性相关的疾病、紊乱和症状的方法。淀粉样变性指与A-beta蛋白异常沉积相关的一系列疾病、紊乱和症状。
• [EN] SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS<br/>[FR] UREE ET CARBAMATE SUBSTITUES, PHENACYL-2-HYDROXY-3-DIAMINOALCANE, ET BENZAMIDE-2-HYDROXY-3-DIAMINOALCANE INHIBITEURS D'ASPARTYL-PROTEASE
  申请人：ELAN PHARM INC

  公开号：WO2005087215A1

  公开（公告）日：2005-09-22

  The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating at least one disease, disorder, and condition associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and condition associated with abnormal deposition of A-beta protein.

  这项发明涉及乙酰2-羟基-1,3-二氨基螺环己烷及其衍生物，可用于治疗与淀粉样变性相关的至少一种疾病、紊乱和病况。淀粉样变性指与A-beta蛋白异常沉积相关的一系列疾病、紊乱和病况。
• Asymmetric Synthesis of Fluorinated Allenes by Rhodium‐Catalyzed Enantioselective Alkylation/Defluorination of Propargyl Difluorides with Alkylzincs
  作者：Jia Sheng Ng、Tamio Hayashi

  DOI：10.1002/anie.202109290

  日期：2021.9.13

  The reaction of propargyl difluorides R1CF2C≡CR2 with alkylzincs R3ZnCl giving axially chiral fluorinated allenes R1FC=C=CR2R3 with high enantioselectivity (up to 99 % ee) was found to be catalyzed by a chiral diene/rhodium complex. A key step in the catalytic cycle is selective elimination of one of the enantiotopic fluorides at the β-position of an alkenyl-Rh intermediate, which is generated by regioselective

  发现炔丙基二氟化物 R 1 CF 2 C≡CR 2与烷基锌 R 3 ZnCl 的反应得到具有高对映选择性（高达 99 % ee）的轴向手性氟化丙二烯 R 1 FC=C=CR 2 R 3手性二烯/铑配合物。催化循环中的一个关键步骤是选择性消除烯基-Rh 中间体 β 位的一种对映氟化物，它是通过将 R 3 -Rh区域选择性加成到起始二氟化物的三键上而产生的。
• Substituted Pyrano [2,3-b] Pyridinamine compounds as beta-secretase modulators and methods of use
  申请人：Graceffa Russell

  公开号：US20100120774A1

  公开（公告）日：2010-05-13

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , X and Z are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formula II, intermediates and processes useful for the preparation of compounds of Formulas I and II.

  本发明包括一类新化合物，用于调节Beta-分泌酶酶活性，治疗由Beta-分泌酶介导的疾病，包括阿尔茨海默病（AD）及相关疾病。在一个实施例中，这些化合物具有一般的化学式I，其中R1、R2、R3、R4、R5、A1、A2、A3、A4、X和Z在此处被定义。该发明还包括将这些化合物用于治疗与beta-分泌酶蛋白活性相关的疾病和情况的药物组合物。这些疾病包括阿尔茨海默病（AD）、认知缺陷和损伤、精神分裂症和其他类似的中枢神经系统疾病。该发明还包括化学式II的进一步实施例，以及有用于制备化学式I和II化合物的中间体和工艺。